Literature DB >> 28421849

Infliximab crystal structures reveal insights into self-association.

Thomas F Lerch1, Penelope Sharpe2, Stephen J Mayclin3, Thomas E Edwards3, Eunhee Lee2, Hugh D Conlon2, Sharon Polleck2, Jason C Rouse2, Yin Luo2, Qin Zou1.   

Abstract

Aggregation and self-association in protein-based biotherapeutics are critical quality attributes that are tightly controlled by the manufacturing process. Aggregates have the potential to elicit immune reactions, including neutralizing anti-drug antibodies, which can diminish the drug's efficacy upon subsequent dosing. The structural basis of reversible self-association, a form of non-covalent aggregation in the native state, is only beginning to emerge for many biologics and is often unique to a given molecule. In the present study, crystal structures of the infliximab (Remicade) Fc and Fab domains were determined. The Fab domain structures are the first to be reported in the absence of the antigen (i.e., tumor necrosis factor), and are consistent with a mostly rigid complementarity-determining region loop structure and rotational flexibility between variable and constant regions. A potential self-association interface is conserved in two distinct crystal forms of the Fab domain, and solution studies further demonstrate that reversible self-association of infliximab is mediated by the Fab domain. The crystal structures and corresponding solution studies help rationalize the propensity for infliximab to self-associate and provide insights for the design of improved control strategies in biotherapeutics development.

Entities:  

Keywords:  Aggregation; SEC; analytical ultracentrifugation; biophysical; biotherapeutic; crystallography; infliximab; remicade; self-association; structure

Mesh:

Substances:

Year:  2017        PMID: 28421849      PMCID: PMC5524157          DOI: 10.1080/19420862.2017.1320463

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  30 in total

1.  Characterizing protein-protein interactions by sedimentation velocity analytical ultracentrifugation.

Authors:  Patrick H Brown; Andrea Balbo; Peter Schuck
Journal:  Curr Protoc Immunol       Date:  2008-05

2.  Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs.

Authors:  Friederike Plath; Philippe Ringler; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E Lauer; Arne C Rufer; Melissa A Graewert; Dmitri Svergun; Gerald Gellermann; Christof Finkler; Jan O Stracke; Atanas Koulov; Volker Schnaible
Journal:  MAbs       Date:  2016-03-31       Impact factor: 5.857

3.  Pre-study and in-study validation of a size-exclusion chromatography method with different detection modes for the analysis of monoclonal antibody aggregates.

Authors:  Alexis Oliva; Jose B Fariña; Matías Llabrés
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-04-13       Impact factor: 3.205

Review 4.  A review of the use of infliximab to manage cutaneous dermatoses.

Authors:  Aditya K Gupta; Alayne R Skinner
Journal:  J Cutan Med Surg       Date:  2004-05-04       Impact factor: 2.092

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

6.  Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.

Authors:  Shuaiyi Liang; Jianxin Dai; Sheng Hou; Lishu Su; Dapeng Zhang; Huaizu Guo; Shi Hu; Hao Wang; Zihe Rao; Yajun Guo; Zhiyong Lou
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

7.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

8.  Identification of properties important to protein aggregation using feature selection.

Authors:  Yaping Fang; Shan Gao; David Tai; C Russell Middaugh; Jianwen Fang
Journal:  BMC Bioinformatics       Date:  2013-10-28       Impact factor: 3.169

9.  Small-angle x-ray scattering screening complements conventional biophysical analysis: comparative structural and biophysical analysis of monoclonal antibodies IgG1, IgG2, and IgG4.

Authors:  Xinsheng Tian; Annette E Langkilde; Matthias Thorolfsson; Hanne B Rasmussen; Bente Vestergaard
Journal:  J Pharm Sci       Date:  2014-04-02       Impact factor: 3.534

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  8 in total

1.  Fab is the most efficient format to express functional antibodies by yeast surface display.

Authors:  Coline Sivelle; Raphaël Sierocki; Kelly Ferreira-Pinto; Stéphanie Simon; Bernard Maillere; Hervé Nozach
Journal:  MAbs       Date:  2018-05-24       Impact factor: 5.857

Review 2.  Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.

Authors:  Heejin Lim; Sang Hyung Lee; Hyun Tae Lee; Jee Un Lee; Ji Young Son; Woori Shin; Yong-Seok Heo
Journal:  Int J Mol Sci       Date:  2018-03-07       Impact factor: 5.923

3.  Structural analysis of glycoproteins: building N-linked glycans with Coot.

Authors:  Paul Emsley; Max Crispin
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-04-06       Impact factor: 7.652

4.  Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates.

Authors:  Hannah Morgan; Su-Yi Tseng; Yann Gallais; Margret Leineweber; Pascale Buchmann; Sabrina Riccardi; Myriam Nabhan; Jeannette Lo; Zaahira Gani; Natacha Szely; Cornelia S Zhu; Ming Yang; Andrea Kiessling; Hans-Werner Vohr; Marc Pallardy; Fred Aswad; Isabelle Turbica
Journal:  Front Immunol       Date:  2019-03-28       Impact factor: 7.561

Review 5.  Integrative Approaches in Structural Biology: A More Complete Picture from the Combination of Individual Techniques.

Authors:  Linda Cerofolini; Marco Fragai; Enrico Ravera; Christoph A Diebolder; Ludovic Renault; Vito Calderone
Journal:  Biomolecules       Date:  2019-08-14

Review 6.  Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates.

Authors:  Myriam Nabhan; Marc Pallardy; Isabelle Turbica
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

7.  HLAII peptide presentation of infliximab increases when complexed with TNF.

Authors:  Andrea Casasola-LaMacchia; Robert Joseph Seward; Sophie Tourdot; Matthew Willetts; Gary Kruppa; Michael J Agostino; Gabrielle Bergeron; Nathalie Ahyi-Amendah; Andrew Ciarla; Zhaojiang Lu; Hai-Young Kim; Timothy P Hickling; Hendrik Neubert
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

8.  Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar.

Authors:  Thomas F Lerch; Penelope Sharpe; Stephen J Mayclin; Thomas E Edwards; Sharon Polleck; Jason C Rouse; Qin Zou; Hugh D Conlon
Journal:  BioDrugs       Date:  2020-02       Impact factor: 5.807

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.